Altered oncomodules underlie chromatin regulatory factors driver mutations

Chromatin regulatory factors (CRFs), are known to be involved in tumorigenesis in several cancer types. Nevertheless, the molecular mechanisms through which driver alterations of CRFs cause tumorigenesis remain unknown. Here, we developed a CRFs Oncomodules Discovery approach, which mines several so...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget 2016-05, Vol.7 (21), p.30748-30759
Hauptverfasser: Frigola, Joan, Iturbide, Ane, Lopez-Bigas, Nuria, Peiro, Sandra, Gonzalez-Perez, Abel
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 30759
container_issue 21
container_start_page 30748
container_title Oncotarget
container_volume 7
creator Frigola, Joan
Iturbide, Ane
Lopez-Bigas, Nuria
Peiro, Sandra
Gonzalez-Perez, Abel
description Chromatin regulatory factors (CRFs), are known to be involved in tumorigenesis in several cancer types. Nevertheless, the molecular mechanisms through which driver alterations of CRFs cause tumorigenesis remain unknown. Here, we developed a CRFs Oncomodules Discovery approach, which mines several sources of cancer genomics and perturbaomics data. The approach prioritizes sets of genes significantly miss-regulated in primary tumors (oncomodules) bearing mutations of driver CRFs. We applied the approach to eleven TCGA tumor cohorts and uncovered oncomodules potentially associated to mutations of five driver CRFs in three cancer types. Our results revealed, for example, the potential involvement of the mTOR pathway in the development of tumors with loss-of-function mutations of MLL2 in head and neck squamous cell carcinomas. The experimental validation that MLL2 loss-of-function increases the sensitivity of cancer cell lines to mTOR inhibition lends further support to the validity of our approach. The potential oncogenic modules detected by our approach may guide experiments proposing ways to indirectly target driver mutations of CRFs.
doi_str_mv 10.18632/oncotarget.8752
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5058714</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1816630517</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-61644ea1eef24535920f65512143300d93aa96c298d028f0b8ac6543bba50dcc3</originalsourceid><addsrcrecordid>eNpVUU1PwzAMjRAIprE7J9Qjl418OU0vSBPiU0hc4BxlqTuK2mYkKdL-Pd0YAyxZtmW_Z1uPkDNGZ0wrwS9953yyYYlppnPgB2TECllMOYA4_JOfkEmM73QwkLnmxTE54TktAHIYkcd5kzBgmW3IWl_2Dcas70oMTY2Zewu-tanusoDLvrHJh3VWWTfEmJWh_sSQtX0aJnwXT8lRZZuIk10ck9fbm5fr--nT893D9fxp6qTQaaqYkhItQ6y4BAEFp5UCYJxJISgtC2FtoRwvdEm5ruhCW6dAisXCAi2dE2Ny9c276hctlg67FGxjVqFubVgbb2vzv9PVb2bpPw1Q0PmwZUzYN4GLvTMBHQZn0xa4LzbOac6NYBK4GjAXu6XBf_QYk2nr6LBpbIe-j4ZpppSgwPJhlO7og48xYLU_jVGzVc78Kmc2yg2Q878v7QE_OokvMoKY9A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1816630517</pqid></control><display><type>article</type><title>Altered oncomodules underlie chromatin regulatory factors driver mutations</title><source>MEDLINE</source><source>PubMed Central Open Access</source><source>Recercat</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free E- Journals</source><creator>Frigola, Joan ; Iturbide, Ane ; Lopez-Bigas, Nuria ; Peiro, Sandra ; Gonzalez-Perez, Abel</creator><creatorcontrib>Frigola, Joan ; Iturbide, Ane ; Lopez-Bigas, Nuria ; Peiro, Sandra ; Gonzalez-Perez, Abel</creatorcontrib><description>Chromatin regulatory factors (CRFs), are known to be involved in tumorigenesis in several cancer types. Nevertheless, the molecular mechanisms through which driver alterations of CRFs cause tumorigenesis remain unknown. Here, we developed a CRFs Oncomodules Discovery approach, which mines several sources of cancer genomics and perturbaomics data. The approach prioritizes sets of genes significantly miss-regulated in primary tumors (oncomodules) bearing mutations of driver CRFs. We applied the approach to eleven TCGA tumor cohorts and uncovered oncomodules potentially associated to mutations of five driver CRFs in three cancer types. Our results revealed, for example, the potential involvement of the mTOR pathway in the development of tumors with loss-of-function mutations of MLL2 in head and neck squamous cell carcinomas. The experimental validation that MLL2 loss-of-function increases the sensitivity of cancer cell lines to mTOR inhibition lends further support to the validity of our approach. The potential oncogenic modules detected by our approach may guide experiments proposing ways to indirectly target driver mutations of CRFs.</description><identifier>ISSN: 1949-2553</identifier><identifier>EISSN: 1949-2553</identifier><identifier>DOI: 10.18632/oncotarget.8752</identifier><identifier>PMID: 27095575</identifier><language>eng</language><publisher>United States: Impact Journals</publisher><subject>Carcinogenesis - genetics ; Chromatin - metabolism ; Computational Biology ; Càncer ; Datasets as Topic ; DNA-Binding Proteins - genetics ; Gene Expression Profiling - methods ; Gene Expression Regulation, Neoplastic ; Genomics - methods ; Genètica ; Humans ; Mutation ; Neoplasm Proteins - genetics ; Neoplasms - genetics ; Oncogenes - genetics ; Oncologia ; Research Paper ; Signal Transduction - genetics ; TOR Serine-Threonine Kinases - antagonists &amp; inhibitors ; TOR Serine-Threonine Kinases - metabolism</subject><ispartof>Oncotarget, 2016-05, Vol.7 (21), p.30748-30759</ispartof><rights>Copyright @ 2016 Impact Journals, LLC. All site content, except where otherwise noted, is licensed under a https://creativecommons.org/licenses/by/3.0/ https://creativecommons.org/licenses/by/3.0/ info:eu-repo/semantics/openAccess</rights><rights>Copyright: © 2016 Frigola et al. 2016</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-61644ea1eef24535920f65512143300d93aa96c298d028f0b8ac6543bba50dcc3</citedby><cites>FETCH-LOGICAL-c438t-61644ea1eef24535920f65512143300d93aa96c298d028f0b8ac6543bba50dcc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058714/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058714/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,26974,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27095575$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Frigola, Joan</creatorcontrib><creatorcontrib>Iturbide, Ane</creatorcontrib><creatorcontrib>Lopez-Bigas, Nuria</creatorcontrib><creatorcontrib>Peiro, Sandra</creatorcontrib><creatorcontrib>Gonzalez-Perez, Abel</creatorcontrib><title>Altered oncomodules underlie chromatin regulatory factors driver mutations</title><title>Oncotarget</title><addtitle>Oncotarget</addtitle><description>Chromatin regulatory factors (CRFs), are known to be involved in tumorigenesis in several cancer types. Nevertheless, the molecular mechanisms through which driver alterations of CRFs cause tumorigenesis remain unknown. Here, we developed a CRFs Oncomodules Discovery approach, which mines several sources of cancer genomics and perturbaomics data. The approach prioritizes sets of genes significantly miss-regulated in primary tumors (oncomodules) bearing mutations of driver CRFs. We applied the approach to eleven TCGA tumor cohorts and uncovered oncomodules potentially associated to mutations of five driver CRFs in three cancer types. Our results revealed, for example, the potential involvement of the mTOR pathway in the development of tumors with loss-of-function mutations of MLL2 in head and neck squamous cell carcinomas. The experimental validation that MLL2 loss-of-function increases the sensitivity of cancer cell lines to mTOR inhibition lends further support to the validity of our approach. The potential oncogenic modules detected by our approach may guide experiments proposing ways to indirectly target driver mutations of CRFs.</description><subject>Carcinogenesis - genetics</subject><subject>Chromatin - metabolism</subject><subject>Computational Biology</subject><subject>Càncer</subject><subject>Datasets as Topic</subject><subject>DNA-Binding Proteins - genetics</subject><subject>Gene Expression Profiling - methods</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Genomics - methods</subject><subject>Genètica</subject><subject>Humans</subject><subject>Mutation</subject><subject>Neoplasm Proteins - genetics</subject><subject>Neoplasms - genetics</subject><subject>Oncogenes - genetics</subject><subject>Oncologia</subject><subject>Research Paper</subject><subject>Signal Transduction - genetics</subject><subject>TOR Serine-Threonine Kinases - antagonists &amp; inhibitors</subject><subject>TOR Serine-Threonine Kinases - metabolism</subject><issn>1949-2553</issn><issn>1949-2553</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>XX2</sourceid><recordid>eNpVUU1PwzAMjRAIprE7J9Qjl418OU0vSBPiU0hc4BxlqTuK2mYkKdL-Pd0YAyxZtmW_Z1uPkDNGZ0wrwS9953yyYYlppnPgB2TECllMOYA4_JOfkEmM73QwkLnmxTE54TktAHIYkcd5kzBgmW3IWl_2Dcas70oMTY2Zewu-tanusoDLvrHJh3VWWTfEmJWh_sSQtX0aJnwXT8lRZZuIk10ck9fbm5fr--nT893D9fxp6qTQaaqYkhItQ6y4BAEFp5UCYJxJISgtC2FtoRwvdEm5ruhCW6dAisXCAi2dE2Ny9c276hctlg67FGxjVqFubVgbb2vzv9PVb2bpPw1Q0PmwZUzYN4GLvTMBHQZn0xa4LzbOac6NYBK4GjAXu6XBf_QYk2nr6LBpbIe-j4ZpppSgwPJhlO7og48xYLU_jVGzVc78Kmc2yg2Q878v7QE_OokvMoKY9A</recordid><startdate>20160524</startdate><enddate>20160524</enddate><creator>Frigola, Joan</creator><creator>Iturbide, Ane</creator><creator>Lopez-Bigas, Nuria</creator><creator>Peiro, Sandra</creator><creator>Gonzalez-Perez, Abel</creator><general>Impact Journals</general><general>Impact Journals LLC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>XX2</scope><scope>5PM</scope></search><sort><creationdate>20160524</creationdate><title>Altered oncomodules underlie chromatin regulatory factors driver mutations</title><author>Frigola, Joan ; Iturbide, Ane ; Lopez-Bigas, Nuria ; Peiro, Sandra ; Gonzalez-Perez, Abel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-61644ea1eef24535920f65512143300d93aa96c298d028f0b8ac6543bba50dcc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Carcinogenesis - genetics</topic><topic>Chromatin - metabolism</topic><topic>Computational Biology</topic><topic>Càncer</topic><topic>Datasets as Topic</topic><topic>DNA-Binding Proteins - genetics</topic><topic>Gene Expression Profiling - methods</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Genomics - methods</topic><topic>Genètica</topic><topic>Humans</topic><topic>Mutation</topic><topic>Neoplasm Proteins - genetics</topic><topic>Neoplasms - genetics</topic><topic>Oncogenes - genetics</topic><topic>Oncologia</topic><topic>Research Paper</topic><topic>Signal Transduction - genetics</topic><topic>TOR Serine-Threonine Kinases - antagonists &amp; inhibitors</topic><topic>TOR Serine-Threonine Kinases - metabolism</topic><toplevel>online_resources</toplevel><creatorcontrib>Frigola, Joan</creatorcontrib><creatorcontrib>Iturbide, Ane</creatorcontrib><creatorcontrib>Lopez-Bigas, Nuria</creatorcontrib><creatorcontrib>Peiro, Sandra</creatorcontrib><creatorcontrib>Gonzalez-Perez, Abel</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Recercat</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncotarget</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Frigola, Joan</au><au>Iturbide, Ane</au><au>Lopez-Bigas, Nuria</au><au>Peiro, Sandra</au><au>Gonzalez-Perez, Abel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Altered oncomodules underlie chromatin regulatory factors driver mutations</atitle><jtitle>Oncotarget</jtitle><addtitle>Oncotarget</addtitle><date>2016-05-24</date><risdate>2016</risdate><volume>7</volume><issue>21</issue><spage>30748</spage><epage>30759</epage><pages>30748-30759</pages><issn>1949-2553</issn><eissn>1949-2553</eissn><abstract>Chromatin regulatory factors (CRFs), are known to be involved in tumorigenesis in several cancer types. Nevertheless, the molecular mechanisms through which driver alterations of CRFs cause tumorigenesis remain unknown. Here, we developed a CRFs Oncomodules Discovery approach, which mines several sources of cancer genomics and perturbaomics data. The approach prioritizes sets of genes significantly miss-regulated in primary tumors (oncomodules) bearing mutations of driver CRFs. We applied the approach to eleven TCGA tumor cohorts and uncovered oncomodules potentially associated to mutations of five driver CRFs in three cancer types. Our results revealed, for example, the potential involvement of the mTOR pathway in the development of tumors with loss-of-function mutations of MLL2 in head and neck squamous cell carcinomas. The experimental validation that MLL2 loss-of-function increases the sensitivity of cancer cell lines to mTOR inhibition lends further support to the validity of our approach. The potential oncogenic modules detected by our approach may guide experiments proposing ways to indirectly target driver mutations of CRFs.</abstract><cop>United States</cop><pub>Impact Journals</pub><pmid>27095575</pmid><doi>10.18632/oncotarget.8752</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1949-2553
ispartof Oncotarget, 2016-05, Vol.7 (21), p.30748-30759
issn 1949-2553
1949-2553
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5058714
source MEDLINE; PubMed Central Open Access; Recercat; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free E- Journals
subjects Carcinogenesis - genetics
Chromatin - metabolism
Computational Biology
Càncer
Datasets as Topic
DNA-Binding Proteins - genetics
Gene Expression Profiling - methods
Gene Expression Regulation, Neoplastic
Genomics - methods
Genètica
Humans
Mutation
Neoplasm Proteins - genetics
Neoplasms - genetics
Oncogenes - genetics
Oncologia
Research Paper
Signal Transduction - genetics
TOR Serine-Threonine Kinases - antagonists & inhibitors
TOR Serine-Threonine Kinases - metabolism
title Altered oncomodules underlie chromatin regulatory factors driver mutations
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T21%3A27%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Altered%20oncomodules%20underlie%20chromatin%20regulatory%20factors%20driver%20mutations&rft.jtitle=Oncotarget&rft.au=Frigola,%20Joan&rft.date=2016-05-24&rft.volume=7&rft.issue=21&rft.spage=30748&rft.epage=30759&rft.pages=30748-30759&rft.issn=1949-2553&rft.eissn=1949-2553&rft_id=info:doi/10.18632/oncotarget.8752&rft_dat=%3Cproquest_pubme%3E1816630517%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1816630517&rft_id=info:pmid/27095575&rfr_iscdi=true